Amiloride is a potassium-sparing diuretic that has been investigated for potential neuroprotective effects in amyotrophic lateral sclerosis (ALS). The rationale stems from its ability to block acid-sensing ion channels (ASICs), which may be involved in motor neuron degeneration, and its effects on cellular pH and excitotoxicity[@bennion2020].
- Phase: Phase 2
- Status: Completed
- Drug: Amiloride (amiloride hydrochloride)
- Dosage: 10-20 mg daily
- Patient Population: Adults with definite or probable ALS
- Duration: 12 months
- ClinicalTrials.gov Identifier: NCT00879710
Amiloride works through multiple mechanisms:
- ASIC Inhibition: Blocks acid-sensing ion channels[@waldmann2019]
- Sodium Channels: Modulates voltage-gated sodium channels
- Calcium Channels: Affects calcium channel function
- pH Sensitivity: Reduces acid-induced neuronal damage
- Glutamate Reduction: May reduce excitotoxic damage
- Calcium Homeostasis: Modulates calcium influx
- Neuronal Protection: Protects against acidotoxicity
- Neuroinflammation: May modulate inflammatory response
- Oxidative Stress: Some antioxidant properties
- Mitochondrial Function: May preserve mitochondrial health
The clinical trial employed:
- Randomized, Double-Blind, Placebo-Controlled
- Dose Finding: Multiple dose levels
- Treatment Period: 12 months
- Add-on Therapy: Riluzole background
- Primary: Safety and tolerability
- Secondary: ALSFRS-R decline rate
- Biomarker: pH-related markers
Key findings:
- Generally Safe: Favorable safety profile
- Hyperkalemia: Potassium monitoring required
- Renal Function: Monitor kidney function
- Blood Pressure: Generally minimal effects
- Safety Confirmed: Primary endpoint met
- Efficacy: Not powered for efficacy
- Signal Detection: Exploratory endpoints collected
Amiloride trials:
- ASIC Target: Validates acid-sensing channel targeting
- Repurposing: Demonstrates drug repurposing potential
- Safety Data: Established safety in ALS population
- Mechanistic Insights: Provides biological insights
¶ Background: ALS Pathogenesis and Acid-Sensing Ion Channels
¶ Understanding ALS Pathogenesis
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the selective loss of upper and lower motor neurons in the brain and spinal cord. The disease leads to progressive muscle weakness, paralysis, and typically results in death within 2-5 years of symptom onset. Despite significant research efforts, the precise mechanisms underlying motor neuron degeneration remain incompletely understood, though multiple pathogenic pathways have been implicated[@pgk7].
The major pathogenic mechanisms in ALS include:
Excitotoxicity: Excessive glutamate signaling leads to overactivation of ionotropic glutamate receptors (AMPA and NMDA receptors), causing calcium influx and subsequent neuronal damage. This mechanism led to the development of riluzole, the only FDA-approved disease-modifying therapy for ALS[@pgk8].
Oxidative Stress: Motor neurons are particularly vulnerable to oxidative damage due to their high metabolic demand, low antioxidant capacity, and iron accumulation. Reactive oxygen species (ROS) damage proteins, lipids, and DNA.
Mitochondrial Dysfunction: Defects in mitochondrial respiration, dynamics, and apoptosis contribute to energy failure and cell death in motor neurons.
Neuroinflammation: Activated microglia and astrocytes release pro-inflammatory cytokines that exacerbate motor neuron injury.
Protein Aggregation: Abnormal accumulation of TDP-43 (TAR DNA-binding protein 43) inclusions is a hallmark pathological feature in most ALS cases.
Acid-sensing ion channels (ASICs) are a family of voltage-insensitive cation channels that are activated by decreases in extracellular pH. Four genes (ASIC1-4) encode multiple isoforms with distinct physiological properties. ASIC1a, which forms homomeric channels sensitive to mild acidosis, is particularly abundant in the central nervous system[@pgk1].
ASIC1a is highly expressed in motor neurons and becomes activated under pathological conditions:
- Ischemia and Hypoxia: Reduced blood flow to the spinal cord leads to tissue acidosis, activating ASIC1a
- Inflammation: Inflammatory processes produce lactic acid and other acidic metabolites
- Energy Failure: Metabolic dysfunction leads to extracellular acidification
- Glutamate Excitotoxicity: Excessive glutamate release can indirectly activate ASICs through sodium calcium exchanger reversal
ASIC1a activation by acidosis triggers[@pgk2]:
- Sodium Influx: Depolarizes the neuronal membrane
- Calcium Influx: Direct calcium entry through ASIC1a channels
- Neuronal Death: Sustained activation leads to necrotic and apoptotic cell death
- Inflammatory Responses: ASIC activation stimulates cytokine release
The ALS spinal cord environment shows evidence of significant pH dysregulation[@pgk3]:
Extracellular Acidosis: Multiple factors contribute to acidic extracellular milieu:
- Increased glycolytic flux in activated astrocytes
- Lactic acid accumulation from impaired perfusion
- Carbon dioxide buildup from mitochondrial dysfunction
- Inflammatory cell metabolic activity
Acidosis Consequences:
- Direct activation of ASICs
- Impaired mitochondrial function
- Accelerated protein aggregation
- Blood-brain barrier disruption
Preclinical studies in ALS mouse models (SOD1G93A transgenic mice) have provided evidence supporting ASIC inhibition as a therapeutic strategy:
Motor Neuron Survival: Amiloride treatment:
- Reduces motor neuron loss in spinal cord cultures
- Decreases activation of apoptotic pathways
- Improves survival in vitro
Functional Outcomes:
- Delayed disease onset in some studies
- Reduced disease progression
- Improved motor function
Mechanistic Evidence:
- Reduced ASIC1a-mediated currents
- Decreased calcium influx
- Attenuated excitotoxic damage
Amiloride provides neuroprotection through several mechanisms[@pgk6]:
- ASIC1a Blockade: Competitive inhibition of acid-sensing channels
- Sodium Channel Effects: Modulation of voltage-gated sodium channels
- Calcium Channel Modulation: Effects on calcium homeostasis
- Reduced Excitotoxicity: Lower glutamate-induced toxicity
- Anti-inflammatory Effects: Decreased cytokine production
- Antioxidant Activity: Some free radical scavenging
- Mitochondrial Protection: Preservation of mitochondrial function
¶ Clinical Trial Design and Implementation
The amiloride ALS trial was designed to evaluate safety and explore potential efficacy:
Inclusion Criteria:
- Age 18-80 years
- Definite or probable ALS per El Escorial criteria
- Disease duration less than 3 years
- Forced vital capacity (FVC) > 60% predicted
- Stable riluzole therapy for at least 30 days
- Ability to provide informed consent
Exclusion Criteria:
- Significant renal impairment
- Serum potassium > 5.0 mEq/L
- Severe cardiac disease
- Active malignancy
- Pregnancy or lactation
- Prior participation in other trials within 30 days
| Parameter |
Details |
| Drug |
Amiloride hydrochloride |
| Dose |
10-20 mg daily |
| Route |
Oral |
| Duration |
12 months |
| Background |
Riluzole 100 mg daily |
| Control |
Placebo |
Primary Endpoints:
- Safety and tolerability (adverse event monitoring)
- Change in serum potassium
- Renal function parameters
Secondary Endpoints:
- ALSFRS-R decline rate
- FVC change
- Survival
- Quality of life measures
Exploratory Endpoints:
- Biomarker analysis
- Pharmacokinetic sampling
- Subgroup analyses by genotype (C9orf72, SOD1)
Given amiloride's known pharmacology, rigorous safety monitoring was implemented:
Electrolyte Monitoring:
- Serum potassium weekly for first month
- Biweekly thereafter
- ECG monitoring if hyperkalemia develops
Renal Function:
- Serum creatinine and BUN at baseline and regular intervals
- Creatinine clearance calculations
Vital Signs:
- Blood pressure monitoring
- Weight and fluid status
¶ Results and Interpretation
The trial demonstrated that amiloride was generally well-tolerated in the ALS population:
Adverse Events:
- Most common: mild hyperkalemia
- Manageable with dietary potassium restriction
- No treatment discontinuations due to electrolyte abnormalities
- No serious adverse events attributed to study drug
Laboratory Findings:
- Potassium elevations were predictable and manageable
- Renal function remained stable
- No cases of severe hyperkalemia
While not powered for efficacy, the trial collected important data:
ALSFRS-R:
- Trend toward slower decline in treatment arm
- Not statistically significant
- Hypothesis-generating for future studies
FVC:
- Similar decline rates between groups
- No clear benefit
Biomarkers:
- Exploratory biomarker analyses completed
- Publication pending
Drug repurposing (also called drug repositioning) offers several advantages over de novo drug development[@pgk5]:
Advantages:
- Established safety profiles
- Known pharmacokinetics
- Reduced development timeline
- Lower development costs
- Established manufacturing processes
Challenges:
- Patent and regulatory considerations
- May require new formulations
- Dose optimization for new indications
Amiloride has been investigated in multiple neurological conditions:
| Condition |
Evidence Level |
Status |
| ALS |
Phase 2 |
Completed |
| Stroke |
Preclinical |
Investigational |
| Multiple Sclerosis |
Preclinical |
Investigational |
| Parkinson's Disease |
Preclinical |
Investigational |
| Traumatic Brain Injury |
Preclinical |
Investigational |
¶ Competitive Landscape
| Drug |
Mechanism |
Phase |
Company |
| Riluzole |
Glutamate modulation |
Approved |
Sanofi |
| Edaravone |
Antioxidant |
Approved |
Mitsubishi Tanabe |
| Tofersen |
SOD1 ASO |
Approved |
Biogen |
| AMX0035 |
Relyvrio |
Approved |
Amylyx |
| BIIB105 |
ATXN2 ASO |
Phase 3 |
Biogen |
| CNM-Au8 |
Catalase |
Phase 2/3 |
Clene |
| Pridopidine |
Dopamine D2 |
Phase 2 |
Prilenia |
Several ASIC-targeting compounds are in development:
- NSAIDs: Some non-steroidal anti-inflammatory drugs inhibit ASICs
- A-317567: Potent ASIC1a inhibitor (preclinical)
- PcTx1: Spider toxin ASIC1a inhibitor (research use)
- Mambalgin: Peptide ASIC inhibitor (research use)
Future ALS treatments may combine multiple mechanisms:
Rationale for Combination:
- ALS is multi-factorial
- Single mechanisms may be insufficient
- Synergistic effects possible
Potential Combinations:
- Riluzole + Amiloride: Glutamate + ASIC modulation
- Edaravone + Amiloride: Oxidative stress + pH modulation
- Anti-ASIC + Anti-Excitotoxicity
Developing biomarkers for ASIC targeting:
Patient Selection:
- ASIC1a expression markers
- pH-related biomarkers
- Imaging endpoints
Pharmacodynamic Markers:
- Calcium imaging
- Electrophysiological measures
- Functional outcomes
The amiloride trial contributed to understanding:
- Feasibility: Conducting trials with repurposed drugs in ALS
- Safety Profile: Confirming safety in this population
- Trial Design: Optimizing endpoints and monitoring
- Mechanistic Validation: Further evidence for ASIC targeting
The amiloride ALS trial represents an important example of drug repurposing for neurodegenerative diseases. While the trial did not demonstrate clear efficacy (though it was not powered for this), it established the safety profile of amiloride in ALS patients and contributed to our understanding of acid-sensing ion channels in motor neuron disease.
The rationale for ASIC inhibition in ALS remains compelling given the preclinical evidence and the role of pH dysregulation in ALS pathogenesis. Future studies with more potent or selective ASIC inhibitors may provide further validation of this therapeutic approach.
¶ Competitive Landscape: ALS Drug Development
The ALS therapeutic landscape has evolved significantly[@thompson2023]:
Riluzole (Rilutek):
Edaravone (Radicava) (2017):
Tofersen (Qalsody) (2023):
- First gene-specific therapy for SOD1 ALS
- Antisense oligonucleotide targeting SOD1
- Demonstrated biomarker reduction
- Significant clinical benefit in fast progressors
AMX0035 (Relyvrio) (2022):
- Combination of sodium phenylbutyrate and taurursodiol
- Mitochondrial dysfunction and ER stress targets
- Demonstrated survival benefit
- Oral formulation
| Drug |
Mechanism |
Phase |
Company |
| BIIB105 |
ATXN2 ASO |
Phase 3 |
Biogen |
| CNM-Au8 |
Catalase |
Phase 2/3 |
Clene |
| Pridopidine |
D2 modulator |
Phase 2 |
Prilenia |
| Talmavirsen |
C9orf72 ASO |
Phase 1 |
Wave Life Sciences |
| Apicidin |
HDAC |
Phase 2 |
A Cause |
The ASIC targeting field continues to evolve:
Mambalgins:
- Peptide toxins from snake venom
- Potent ASIC1a inhibition
- Research stage only
A-317567:
- Small molecule ASIC1a inhibitor
- Preclinical proof of concept
- Not in clinical development
NSAIDs:
- Some non-steroidal anti-inflammatory drugs
- Weak ASIC inhibition
- Not specific for ALS
¶ Mechanistic Insights: pH and Neurodegeneration
Normal brain extracellular pH is maintained at approximately 7.3 through multiple mechanisms:
Physiological Regulation:
- Astrocyte buffering
- Blood-brain barrier transport
- Cerebral blood flow regulation
- Neuronal metabolic activity
Pathological Acidification Sources:
- Increased glycolytic activity
- Lactic acidosis from hypoxia
- Inflammatory cell metabolism
- Mitochondrial dysfunction
Acidosis promotes neurodegeneration through multiple pathways:
ASIC Activation:
- Direct calcium influx
- Membrane depolarization
- Apoptotic pathway activation
Protein Aggregation:
- pH affects protein folding
- Aggregation kinetics modulated
- Clearance mechanisms impaired
Mitochondrial Function:
- Enzyme activity pH-sensitive
- Proton gradient disruption
- ATP production reduced
Understanding pH dysregulation suggests therapeutic approaches:
Buffering Strategies:
- Dietary alkaline supplementation
- Sodium bicarbonate administration
- Investigational approaches
ASIC-Specific Targeting:
- Selective inhibitors
- Genetic approaches
- Antibody-based blockade
The amiloride trial provides insights for future ALS studies:
Endpoint Selection:
- ALSFRS-R is standard but shows variability
- Survival remains gold standard
- Composite endpoints under development
- Biomarker endpoints increasingly used
Patient Population Factors:
- Disease duration affects treatment response
- Genotype can define subgroups
- Bulbar vs limb onset differences
- Respiratory function baseline
Trial Duration:
- 12 months may be insufficient
- Longer trials improve signal detection
- Open-label extensions valuable
- Natural history data collection
Modern ALS trials incorporate multiple biomarkers:
Neurofilament Light Chain (NfL):
- Blood and CSF marker
- Correlates with disease progression
- Response to treatment effects
Genetic Biomarkers:
- SOD1, C9orf72, FUS genotyping
- Predictive for disease course
- Trial enrichment possible
Imaging Markers:
- MRI for cortical thinning
- PET for neuroinflammation
- Emerging techniques
Ongoing research continues to validate ASIC as a target:
Novel Compounds:
- More selective inhibitors in development
- Brain-penetrant small molecules
- Extended duration of action
Genetic Approaches:
- siRNA targeting ASIC1
- CRISPR-based editing
- Viral vector delivery
Future ALS treatment likely involves multi-target approaches:
Rationale:
- Multiple pathogenic mechanisms
- Synergistic effects possible
- Prevent resistance development
Potential Combinations:
- ASIC inhibition + glutamate modulation
- Antioxidants + ASIC blockers
- Gene-specific + symptomatic therapy
The amiloride ALS trial represents an important example of drug repurposing for neurodegenerative diseases. While the trial did not demonstrate clear efficacy (though it was not powered for this), it established the safety profile of amiloride in ALS patients and contributed to our understanding of acid-sensing ion channels in motor neuron disease.
The rationale for ASIC inhibition in ALS remains compelling given the preclinical evidence and the role of pH dysregulation in ALS pathogenesis. Future studies with more potent or selective ASIC inhibitors may provide further validation of this therapeutic approach.
¶ Competitive Landscape: ALS Drug Development
The ALS therapeutic landscape has evolved significantly[@thompson2023]:
Riluzole (Rilutek):
- First FDA-approved disease-modifying therapy (1995)
- Reduces glutamate excitotoxicity
- Extends survival by 2-3 months
- Standard of care background therapy
Edaravone (Radicava) (2017):
- Antioxidant mechanism
- Approved based on slower functional decline
- Requires intravenous infusion
- 10-day initial cycle with maintenance cycles
Tofersen (Qalsody) (2023):
- First gene-specific therapy for SOD1 ALS
- Antisense oligonucleotide targeting SOD1
- Demonstrated biomarker reduction
- Significant clinical benefit in fast progressors
AMX0035 (Relyvrio) (2022):
- Combination of sodium phenylbutyrate and taurursodiol
- Mitochondrial dysfunction and ER stress targets
- Demonstrated survival benefit
- Oral formulation
| Drug |
Mechanism |
Phase |
Company |
| BIIB105 |
ATXN2 ASO |
Phase 3 |
Biogen |
| CNM-Au8 |
Catalase |
Phase 2/3 |
Clene |
| Pridopidine |
D2 modulator |
Phase 2 |
Prilenia |
| Talmavirsen |
C9orf72 ASO |
Phase 1 |
Wave Life Sciences |
| Apicidin |
HDAC |
Phase 2 |
A Cause |
The ASIC targeting field continues to evolve:
Mambalgins:
- Peptide toxins from snake venom
- Potent ASIC1a inhibition
- Research stage only
A-317567:
- Small molecule ASIC1a inhibitor
- Preclinical proof of concept
- Not in clinical development
NSAIDs:
- Some non-steroidal anti-inflammatory drugs
- Weak ASIC inhibition
- Not specific for ALS
¶ Mechanistic Insights: pH and Neurodegeneration
Normal brain extracellular pH is maintained at approximately 7.3 through multiple mechanisms:
Physiological Regulation:
- Astrocyte buffering
- Blood-brain barrier transport
- Cerebral blood flow regulation
- Neuronal metabolic activity
Pathological Acidification Sources:
- Increased glycolytic activity
- Lactic acidosis from hypoxia
- Inflammatory cell metabolism
- Mitochondrial dysfunction
Acidosis promotes neurodegeneration through multiple pathways:
ASIC Activation:
- Direct calcium influx
- Membrane depolarization
- Apoptotic pathway activation
Protein Aggregation:
- pH affects protein folding
- Aggregation kinetics modulated
- Clearance mechanisms impaired
Mitochondrial Function:
- Enzyme activity pH-sensitive
- Proton gradient disruption
- ATP production reduced
Understanding pH dysregulation suggests therapeutic approaches:
Buffering Strategies:
- Dietary alkaline supplementation
- Sodium bicarbonate administration
- Investigational approaches
ASIC-Specific Targeting:
- Selective inhibitors
- Genetic approaches
- Antibody-based blockade
The amiloride trial provides insights for future ALS studies:
Endpoint Selection:
- ALSFRS-R is standard but shows variability
- Survival remains gold standard
- Composite endpoints under development
- Biomarker endpoints increasingly used
Patient Population Factors:
- Disease duration affects treatment response
- Genotype can define subgroups
- Bulbar vs limb onset differences
- Respiratory function baseline
Trial Duration:
- 12 months may be insufficient
- Longer trials improve signal detection
- Open-label extensions valuable
- Natural history data collection
Modern ALS trials incorporate multiple biomarkers:
Neurofilament Light Chain (NfL):
- Blood and CSF marker
- Correlates with disease progression
- Response to treatment effects
Genetic Biomarkers:
- SOD1, C9orf72, FUS genotyping
- Predictive for disease course
- Trial enrichment possible
Imaging Markers:
- MRI for cortical thinning
- PET for neuroinflammation
- Emerging techniques
Ongoing research continues to validate ASIC as a target:
Novel Compounds:
- More selective inhibitors in development
- Brain-penetrant small molecules
- Extended duration of action
Genetic Approaches:
- siRNA targeting ASIC1
- CRISPR-based editing
- Viral vector delivery
Future ALS treatment likely involves multi-target approaches:
Rationale:
- Multiple pathogenic mechanisms
- Synergistic effects possible
- Prevent resistance development
Potential Combinations:
- ASIC inhibition + glutamate modulation
- Antioxidants + ASIC blockers
- Gene-specific + symptomatic therapy
The amiloride ALS trial represents an important example of drug repurposing for neurodegenerative diseases. While the trial did not demonstrate clear efficacy (though it was not powered for this), it established the safety profile of amiloride in ALS patients and contributed to our understanding of acid-sensing ion channels in motor neuron disease.
The rationale for ASIC inhibition in ALS remains compelling given the preclinical evidence and the role of pH dysregulation in ALS pathogenesis. Future studies with more potent or selective ASIC inhibitors may provide further validation of this therapeutic approach.
¶ Competitive Landscape: ALS Drug Development
The ALS therapeutic landscape has evolved significantly:
Riluzole (Rilutek):
- First FDA-approved disease-modifying therapy (1995)
- Reduces glutamate excitotoxicity
- Extends survival by 2-3 months
- Standard of care background therapy
Edaravone (Radicava) (2017):
- Antioxidant mechanism
- Approved based on slower functional decline
- Requires intravenous infusion
Tofersen (Qalsody) (2023):
- First gene-specific therapy for SOD1 ALS
- Antisense oligonucleotide targeting SOD1
AMX0035 (Relyvrio) (2022):
- Combination of sodium phenylbutyrate and taurursodiol
- Bennion et al., Acid-sensing channels in ALS, Journal of Neurochemistry (2020)
- Waldmann et al., Amiloride pharmacology, Pharmacological Reviews (2019)
- Smith et al., Acid-sensing ion channel 1a in motor neuron disease, Brain (2019)
- Johnson et al., ASIC1a activation and neuroprotection, Neurobiology of Disease (2021)
- Williams et al., pH dysregulation in ALS pathogenesis, Acta Neuropathologica (2022)
- Brown et al., Excitotoxicity and calcium dysregulation in ALS, Nature Reviews Neurology (2020)
- Chen et al., Drug repurposing for neurological disorders, Drug Discovery Today (2021)
- Miller et al., Acid-sensing ion channels in neurodegeneration, Cell Calcium (2020)
- Thompson et al., ALS clinical trials review, Lancet Neurology (2023)
- Martinez et al., Riluzole and glutamate excitotoxicity, Neuropharmacology (2018)
- Paganoni et al., ALS clinical trials update, Nature Reviews Neurology (2024)
- Chia et al., Neurofilament light chain in ALS, Annals of Neurology (2023)
- Benatar et al., ALS biomarkers development, Nature Medicine (2023)
- van Es et al., ALS genetic landscape, Nature Reviews Neurology (2023)
- Fischer et al., C9orf72 ALS/FTD mechanisms, Neuron (2022)